Article
Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin.
Liver international : official journal of the International Association for the Study of the Liver - 1 Dec 2003
Yang Sheng-Shun, Lai Ming-Yang, Chen Ding-Shinn, Chen Gran-Hum, Kao Jia-Horng
Abstract excerpt
BACKGROUND/AIMS: Combination therapy with interferon (IFN) and ribavirin is the current standard treatment for chronic hepatitis C, but the efficacy is still not satisfactory, especially for genotype 1b. NS5A and E2 proteins of hepatitis C virus (HCV) may repress the IFN-induced RNA-dependent protein kinase (PKR), and thus have the potential to influence the response of HCV to IFN therapy; however, this issue...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
